![](https://investorshub.advfn.com/uicon/48355.png?cb=1551739062)
Wednesday, August 18, 2021 10:43:33 PM
6:41 pm ET August 18, 2021 (Globe Newswire) Print
- Toripalimab plus chemotherapy met primary endpoint with significant improvement in PFS compared to chemotherapy alone -
- Data support the use of toripalimab with chemotherapy as first-line therapy for patients with NSCLC -
- Study to be presented September 13 at IASLC 2021 World Conference on Lung Cancer -
Shanghai Junshi Biosciences Co., Ltd. ("Junshi Biosciences", HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. ("Coherus", Nasdaq: CHRS), today announced positive interim results from the pivotal study "CHOICE-01" (NCT03856411), a randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating toripalimab plus chemotherapy as first-line treatment of advanced squamous or non-squamous non-small cell lung cancer (NSCLC). The interim analysis met the primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression free survival (PFS) per RECIST v1.1 compared to chemotherapy alone.
The results will be summarized September 13 in an oral presentation by Professor Jie Wang, MD, PhD, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, during the Mini Oral Session at the 2021 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer (IASLC). The abstract is now available on the WCLC website.
New York Yankees and Duke Basketball
Recent CHRS News
- Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction • GlobeNewswire Inc. • 06/27/2024 12:26:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:57:54 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:55:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:54:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:52:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:51:30 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:47:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:46:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 10:45:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 01:11:23 PM
- Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors • GlobeNewswire Inc. • 06/05/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 08:05:13 PM
- Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 01:00:00 PM
- Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:51:06 PM
- Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA • GlobeNewswire Inc. • 05/23/2024 01:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/21/2024 09:14:58 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/13/2024 08:35:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:51:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:17:04 PM
- Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:30:11 AM
- Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer • GlobeNewswire Inc. • 05/08/2024 01:00:00 PM
- Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 • GlobeNewswire Inc. • 05/01/2024 08:30:00 PM
- Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 04/24/2024 02:02:18 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM